Phase 4 Peripheral Arterial Disease Trial, Recruiting (NCT04081701)

Phase 4 Peripheral Arterial Disease Trial, Recruiting NCT04081701 Sponsor: Weill Medical College of Cornell University Condition: Peripheral Arterial Disease

Printed from Voxsanity (voxsanity.com.au) — NCT04081701 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Peripheral Arterial Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are 18 years of age or older
People who have been diagnosed with a meningioma (a type of brain tumor) confirmed by a pathology report, and where scans suggest the tumor may have come back or some tumor may remain after treatment
People with certain other types of brain tumors that have a specific protein on their surface (called somatostatin receptor 2), including esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma, or cancers that started elsewhere in the body and spread to the brain — these cases may be included to gather additional research information
People who are not able to have a high-strength (3 Tesla) MRI scan may still be considered, as the trial site can arrange a lower-strength (1.5 Tesla) MRI combined with a different type of scan called a PET/CT (confirm with trial site)

Who may not be able to join:

People who have a medical reason they cannot receive a gadolinium-based contrast dye, which is a substance used to improve MRI scan images
People who have previously had an allergic reaction to the imaging agent used in this trial, called Gallium-68-DOTATATE
People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Jana Ivanidze, MD/Ph.D, Weill Medical College of Cornell University

Phone: 212-746-4587

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04081701

Sponsor: Weill Medical College of Cornell University

Phase: Phase 4

Status: Recruiting

Condition: Peripheral Arterial Disease

Trial contact: 212-746-4587

More information: https://clinicaltrials.gov/study/NCT04081701

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are 18 years of age or older
People who have been diagnosed with a meningioma (a type of brain tumor) confirmed by a pathology report, and where scans suggest the tumor may have come back or some tumor may remain after treatment
People with certain other types of brain tumors that have a specific protein on their surface (called somatostatin receptor 2), including esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma, or cancers that started elsewhere in the body and spread to the brain — these cases may be included to gather additional research information
People who are not able to have a high-strength (3 Tesla) MRI scan may still be considered, as the trial site can arrange a lower-strength (1.5 Tesla) MRI combined with a different type of scan called a PET/CT (confirm with trial site)

Who may not be able to join:

People who have a medical reason they cannot receive a gadolinium-based contrast dye, which is a substance used to improve MRI scan images
People who have previously had an allergic reaction to the imaging agent used in this trial, called Gallium-68-DOTATATE
People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

Weill Medical College of Cornell University

Registry

ClinicalTrials.gov

Start date

4 September 2019

Est. completion

31 December 2038

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Evaluate whether Ga-68-DOTATATE PET/MRI provides additional clinical benefit

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov